GlassScriptPhysician profile
Katherine Cunha
NPI 1699242776
$6,779.48
in general payments reported to CMS, 2019-2025
31 companies · $1,497 in 2025
The $1,497 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,666 · 2022: $1,029 · 2023: $762 · 2024: $1,827 · 2025: $1,497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,085.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,771.59 | 2021-2025 | Tecvayli, Darzalex, Carvykti |
| E.R. Squibb & Sons, L.L.C. | $997.94 | 2021-2025 | Opdivo, Breyanzi, Reblozyl |
| Glaxosmithkline, LLC. | $614.02 | 2021-2025 | Ojjaara, Zejula |
| Astrazeneca Pharmaceuticals LP | $585.61 | 2021-2024 | Lynparza, Calquence |
| Daiichi Sankyo INC. | $270.36 | 2021 | |
| Lilly USA, LLC | $231.60 | 2021 | |
| Pfizer INC. | $229.85 | 2021-2024 | |
| Secura Bio, INC. | $217.73 | 2024 | Copiktra |
| Genzyme Corporation | $133.50 | 2021-2022 | |
| Menarini Silicon Biosystems, INC. | $125.24 | 2024 | |
| Beigene USA, INC. | $125.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2022 | |
| Agios Pharmaceuticals, INC. | $124.96 | 2025 | Pyrukynd |
| Astellas Pharma US INC | $124.25 | 2025 | Padcev |
| Amgen INC. | $117.95 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $116.47 | 2023 | Fruzaqla |
| Foundation Medicine, INC. | $116.05 | 2023 | |
| Caris Mpi, INC. | $113.79 | 2025 | Mi Cancer Seek |
| Gilead Sciences, INC. | $113.46 | 2023 | Trodelvy |
| Aveo Pharmaceuticals, INC. | $106.01 | 2021 | |
| Novartis Pharmaceuticals Corporation | $102.85 | 2025 | |
| Merck Sharp & Dohme LLC | $76.17 | 2021 | |
| Emd Serono, INC. | $71.96 | 2021 | |
| Eisai INC. | $38.87 | 2021 | |
| Abbvie INC. | $22.63 | 2021 | |
| Tersera Therapeutics LLC | $20.81 | 2021 | |
| Dova Pharmaceuticals | $19.67 | 2021 | |
| Boston Scientific Corporation | $18.12 | 2024 | |
| Seagen INC. | $18.12 | 2021 | |
| Celgene Corporation | $15.27 | 2021 | |
| Myovant Sciences INC. | $14.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Cunha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.